Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors

Transplant International

Volumn 18, Issue 5, 2005, Pages 596-603

  Sánchez Fructuoso, Ana I ^a,b   Marques, María ^a   Conesa, José ^a   Ridao, Natalia ^a   Rodríguez, Antolina ^a   Blanco, Julia ^a   Barrientos, Alberto ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Clinical transplantation; Complications of clinical transplantation; Delayed graft function; Immunosuppression; Nonheart beating donors

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; DACLIZUMAB; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; DRUG DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TUMOR; LIPID METABOLISM; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE TUMOR; TREATMENT OUTCOME; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; DONOR; DRUG COMBINATION; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; CREATININE; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; STEROIDS; SURVIVAL RATE; TACROLIMUS; TISSUE DONORS;

EID: 23844549966     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00100.x     Document Type: Article

References (23)

1. Sánchez-Fructuoso AI, Prats D, Naranjo P, et al. Renal transplantation from non-heart beating donors: a promising alternative to enlarge the donor pool. J Am Soc Nephrol 2000; 11: 350.
2. Sanchez-Fructuoso AI, De Miguel Marques M, Prats D, Barrientos A. Non-heart-beating donors: experience from the Hospital Clinico of Madrid. J Nephrol 2003; 16: 387.
3. Weber M, Dindo D, Demartines N, Ambuhl PM, Clavien PA. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002; 347: 248.
4. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
5. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
6. Grinyo JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003; 16: 820.
7. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
8. Sanchez-Fructuoso AI, Naranjo P, Torrente J, et al. Effect of antithymocyte globulin induction treatment on renal transplant outcome. Transplant Proc 1998; 30: 1790.
9. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroid for prevention of acute rejection. Lancet 1995; 345: 1321.
10. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
11. Tricontinental Mycophenolate Mofetil Renal Transplant Study Group 1996. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantion. Transplantation 1996; 61: 1029.
12. Vincenti F, Kirkman R, Light S, Daclizumab Triple Therapy Study Group, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 1700.
13. Vincenti F. Targeting the interleukin-2 receptor in clinical renal transplantation. Graft 1999; 2: 56.
14. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
15. Shapiro R, Randhawa P, Jordan ML, et al. An analysis of early renal transplant protocol biopsies -the high incidence of subclinical tubulitis. Am J Transplant 2001; 1: 47.
16. Matas AJ, Solez K. From first principles - tubulitis in protocol biopsies and learning from history. Am J Transplant 2001; 1: 4.
17. Shaffer D, Langone A, Nylander WA, Goral S, Kizilisik AT, Helderman JH. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17 (Suppl 9): 31.
18. Gentil MA, Osuna A, Capdevila L, Spanish Kidney Transplant of Elderly Donor Study Group, et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. Transplant Proc 2003; 35: 1706.
19. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234.
20. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation 2002; 74: 966.
21. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50.
22. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568.
23. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003; 75: 1260.